Tokyo Tape
Sign in
← Koa Shoji Holdings

Quarterly report · Q1

9273.TEDINET S100PM9S
Period2022-07-01 → 2022-09-30
Filed2022-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
MetricValuePeriodScopeSource row
Revenue¥5.4bn2022-07-01 → 2022-09-30Cons.Net sales
Revenue¥20.4bn2021-07-01 → 2022-06-30Cons.Net sales (5-year summary)
Revenue¥4.8bn2021-07-01 → 2021-09-30Cons.Net sales
Operating income¥1.0bn2022-07-01 → 2022-09-30Cons.Operating income
Operating income¥871m2021-07-01 → 2021-09-30Cons.Operating income
Ordinary income¥979m2022-07-01 → 2022-09-30Cons.Ordinary income
Ordinary income¥3.8bn2021-07-01 → 2022-06-30Cons.Ordinary income loss (5-year summary)
Ordinary income¥876m2021-07-01 → 2021-09-30Cons.Ordinary income
Profit before tax¥979m2022-07-01 → 2022-09-30Cons.Income before income taxes
Profit before tax¥876m2021-07-01 → 2021-09-30Cons.Income before income taxes
Net income (owners)¥606m2022-07-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥2.4bn2021-07-01 → 2022-06-30Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥606m2021-07-01 → 2021-09-30Cons.Profit loss attributable to owners of parent
Net income¥606m2022-07-01 → 2022-09-30Cons.Profit loss
Net income¥606m2021-07-01 → 2021-09-30Cons.Profit loss
Total assets¥26.3bnat 2022-09-30Cons.Assets
Total assets¥26.2bnat 2022-06-30Cons.Assets
Total assets¥24.6bnat 2021-09-30Cons.Total assets (5-year summary)
Total liabilities¥7.4bnat 2022-09-30Cons.Liabilities
Total liabilities¥7.6bnat 2022-06-30Cons.Liabilities
Net assets / equity¥18.8bnat 2022-09-30Cons.Net assets
Net assets / equity¥18.7bnat 2022-06-30Cons.Net assets
Net assets / equity¥16.9bnat 2021-09-30Cons.Net assets (5-year summary)
Cash and deposits¥8.6bnat 2022-09-30Cons.Cash and deposits
Cash and deposits¥9.1bnat 2022-06-30Cons.Cash and deposits
EPS (basic)¥15.292022-07-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥59.552021-07-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥15.292021-07-01 → 2021-09-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio71.8%at 2022-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio71.1%at 2022-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio68.8%at 2021-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 28
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-07-01 → 2022-09-30−¥501m
Reconciling Itemsreconcilingrevenue intersegment2022-07-01 → 2022-09-30−¥501m
Reconciling Itemsreconcilingsegment profit2022-07-01 → 2022-09-30¥6m
jpcrp040300-q1r_E34071-000Drug Substance Sales Businessreportable segmentrevenue2022-07-01 → 2022-09-30¥4.0bn
jpcrp040300-q1r_E34071-000Drug Substance Sales Businessreportable segmentrevenue external2022-07-01 → 2022-09-30¥3.5bn
jpcrp040300-q1r_E34071-000Drug Substance Sales Businessreportable segmentrevenue intersegment2022-07-01 → 2022-09-30¥501m
jpcrp040300-q1r_E34071-000Drug Substance Sales Businessreportable segmentsegment profit2022-07-01 → 2022-09-30¥672m
jpcrp040300-q1r_E34071-000Pharmaceutical Marketing Businessreportable segmentrevenue2022-07-01 → 2022-09-30¥1.9bn
jpcrp040300-q1r_E34071-000Pharmaceutical Marketing Businessreportable segmentrevenue external2022-07-01 → 2022-09-30¥1.9bn
jpcrp040300-q1r_E34071-000Pharmaceutical Marketing Businessreportable segmentsegment profit2022-07-01 → 2022-09-30¥337m
—segment totalrevenue2022-07-01 → 2022-09-30¥5.9bn
—segment totalrevenue external2022-07-01 → 2022-09-30¥5.4bn
—segment totalrevenue intersegment2022-07-01 → 2022-09-30¥501m
—segment totalsegment profit2022-07-01 → 2022-09-30¥1.0bn
Reconciling Itemsreconcilingrevenue2021-07-01 → 2021-09-30−¥498m
Reconciling Itemsreconcilingrevenue intersegment2021-07-01 → 2021-09-30−¥498m
Reconciling Itemsreconcilingsegment profit2021-07-01 → 2021-09-30−¥803,000
jpcrp040300-q1r_E34071-000Drug Substance Sales Businessreportable segmentrevenue2021-07-01 → 2021-09-30¥3.6bn
jpcrp040300-q1r_E34071-000Drug Substance Sales Businessreportable segmentrevenue external2021-07-01 → 2021-09-30¥3.1bn
jpcrp040300-q1r_E34071-000Drug Substance Sales Businessreportable segmentrevenue intersegment2021-07-01 → 2021-09-30¥498m
jpcrp040300-q1r_E34071-000Drug Substance Sales Businessreportable segmentsegment profit2021-07-01 → 2021-09-30¥609m
jpcrp040300-q1r_E34071-000Pharmaceutical Marketing Businessreportable segmentrevenue2021-07-01 → 2021-09-30¥1.7bn
jpcrp040300-q1r_E34071-000Pharmaceutical Marketing Businessreportable segmentrevenue external2021-07-01 → 2021-09-30¥1.7bn
jpcrp040300-q1r_E34071-000Pharmaceutical Marketing Businessreportable segmentsegment profit2021-07-01 → 2021-09-30¥262m
—segment totalrevenue2021-07-01 → 2021-09-30¥5.3bn
—segment totalrevenue external2021-07-01 → 2021-09-30¥4.8bn
—segment totalrevenue intersegment2021-07-01 → 2021-09-30¥498m
—segment totalsegment profit2021-07-01 → 2021-09-30¥871m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 353
ItemContextValueUnit
Shareholders equityPrior1YearInstant18648371000JPY
Shareholders equityCurrentQuarterInstant18818467000JPY
Valuation difference on available for sale securitiesPrior1YearInstant15990000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant16250000JPY
Deferred gains or losses on hedgesPrior1YearInstant1469000JPY
Deferred gains or losses on hedgesCurrentQuarterInstant165000JPY
Valuation and translation adjustmentsPrior1YearInstant17460000JPY
Valuation and translation adjustmentsCurrentQuarterInstant16416000JPY
Net assetsPrior1YearInstant18665832000JPY
Net assetsCurrentQuarterInstant18834883000JPY
Liabilities and net assetsPrior1YearInstant26249934000JPY
Liabilities and net assetsCurrentQuarterInstant26250193000JPY
Net salesPrior1YTDDuration4845773000JPY
Net salesCurrentYTDDuration5358608000JPY
Cost of salesPrior1YTDDuration3478852000JPY
Cost of salesCurrentYTDDuration3837240000JPY
Gross profitPrior1YTDDuration1366921000JPY
Gross profitCurrentYTDDuration1521367000JPY
Selling general and administrative expensesPrior1YTDDuration496386000JPY
Selling general and administrative expensesCurrentYTDDuration506256000JPY
Operating incomePrior1YTDDuration870534000JPY
Operating incomeCurrentYTDDuration1015111000JPY
Interest and dividends income noiPrior1YTDDuration1391000JPY
Interest and dividends income noiCurrentYTDDuration859000JPY
Foreign exchange gains noiPrior1YTDDuration18867000JPY
Foreign exchange gains noiCurrentYTDDuration－JPY
Commission fee noiPrior1YTDDuration3147000JPY
Commission fee noiCurrentYTDDuration3088000JPY
Subsidy income noiPrior1YTDDuration2259000JPY
Subsidy income noiCurrentYTDDuration－JPY
Compensation income noiPrior1YTDDuration226000JPY
Compensation income noiCurrentYTDDuration4922000JPY
Other noiPrior1YTDDuration219000JPY
Other noiCurrentYTDDuration879000JPY
Non operating incomePrior1YTDDuration26112000JPY
Non operating incomeCurrentYTDDuration9749000JPY
Interest expenses noePrior1YTDDuration4483000JPY
Interest expenses noeCurrentYTDDuration2036000JPY
Foreign exchange losses noePrior1YTDDuration－JPY
Foreign exchange losses noeCurrentYTDDuration42725000JPY
Settlement package noePrior1YTDDuration16000000JPY
Settlement package noeCurrentYTDDuration－JPY
Other noePrior1YTDDuration201000JPY
Other noeCurrentYTDDuration784000JPY
Non operating expensesPrior1YTDDuration20684000JPY
Non operating expensesCurrentYTDDuration45545000JPY
Ordinary incomePrior1YTDDuration875963000JPY
Ordinary incomeCurrentYTDDuration979315000JPY
Income before income taxesPrior1YTDDuration875963000JPY
Income before income taxesCurrentYTDDuration979315000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-06-30pass
balance sheet identityconsolidated 2022-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-06-30pass
statement vs summary · net assetsconsolidated 2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-07-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-07-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-07-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2022-06-30pass
statement vs summary · total assetsconsolidated 2022-09-30pass